<b>Conclusions</b>: In patients with HR-positive, HER2-negative breast cancer and liver metastasis, first-line chemotherapy was associated with improved overall survival compared to CDK4/6 inhibitors. The gene discussed is ERBB2; the disease is breast carcinoma.